(VIANEWS) - Alexandria Real Estate Equities (ARE), AbbVie (ABBV), Employers Holdings (EIG) are the highest payout ratio stocks on this list.
We have congregated information concerning stocks with the highest payout ratio so far. The payout ratio in itself isn't a promise of good investment but it's an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. Alexandria Real Estate Equities (ARE)
140.36% Payout Ratio
Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500<sup>®</sup> urban office real estate investment trust ("REIT"), is the first, longest-tenured, and pioneering owner, operator, and developer uniquely focused on collaborative life science, technology, and agtech campuses in AAA innovation cluster locations, with a total market capitalization of $31.9 billion as of December 31, 2020, and an asset base in North America of 49.7 million square feet ("SF"). The asset base in North America includes 31.9 million RSF of operating properties and 3.3 million RSF of Class A properties undergoing construction, 7.1 million RSF of near-term and intermediate-term development and redevelopment projects, and 7.4 million SF of future development projects. Founded in 1994, Alexandria pioneered this niche and has since established a significant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, technology, and agtech campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science, technology, and agtech companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.
Earnings per Share
Alexandria Real Estate Equities' trailing 12 months EPS is $5.74.
PE Ratio
Alexandria Real Estate Equities' trailing 12-month price-to-earnings ratio is 26.23. The purchaser of the shares is therefore investing $26.23 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is an indicator of the business' profitability relative to shareholders' equity, was 3.53%.Annual Top and Bottom Value
Alexandria Real Estate Equities stock was valued at $155.51 at 07.23 EST at 02:23 EST. This is way lower than the 52-week high at $224.95, and much higher than the 52-week low at $126.74.
Growth Estimates Quarters
The company's growth estimates for the present quarter and the next is 59.6% and 186.5%, respectively.2. AbbVie (ABBV)
76.66% Payout Ratio
AbbVie Inc. develops, produces, and markets pharmaceuticals worldwide. HUMIRA is an injectable therapy for autoimmune Behcet's disease; SKYRIZI for moderate to severe plaque psoriasis; RINVOQ to treat mild to moderately severe active rheumatoidarthritis in adults; IMBRUVICA for adults with chronic lymphocyticleukemia (CLL), or small lymphocytic lioma (SLL); and VENCLEXTA to treat chronic HCV genotype 1-6 patients. The company also offers CREON, an exocrine-pancreatic enzyme therapy to treat hypothyroidism. Linzess/Constella is used for irritable bowel syndrome and chronic idiopathic constipation. Lupron can be used for palliative care of advanced prostate cancer and endometriosis. Botox Therapeutic will treat patients with chronic HCV genotype 1-6 infection. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. collaborates with Dragonfly Therapeutics, Inc. It was founded in 2012, and its headquarters are in North Chicago (Illinois).
Earnings Per Share
As for profitability, AbbVie has a trailing twelve months EPS of $2.91.
PE Ratio
AbbVie has a trailing twelve months price to earnings ratio of 56.05. Meaning, the purchaser of the share is investing $56.05 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 92.71%.Annual Top and Bottom Value
AbbVie stock was valued at $163.28 as of 07:24 EST. This is below the 52-week high at $175.91, and much higher than its 52 week low at $125.20.
3. Employers Holdings (EIG)
51.52% Payout Ratio
Employers Holdings, Inc., through its subsidiaries, operates in the commercial property and casualty insurance industry primarily in the United States. It offers workers' compensation insurance to small businesses in low to medium hazard industries. The company markets its products through independent local, regional, and national agents and brokers; alternative distribution channels; and national, regional, and local trade groups and associations, as well as directly to customers. Employers Holdings, Inc. was founded in 2000 and is based in Reno, Nevada.
Earnings Per Share
As for profitability, Employers Holdings has a trailing twelve months EPS of $1.98.
PE Ratio
Employers Holdings has a trailing twelve months price to earnings ratio of 21.73. Meaning, the purchaser of the share is investing $21.73 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.32%.4. Chevron (CVX)
36.82% Payout Ratio
Through its subsidiaries, Chevron Corporation engages in global integrated energy- and chemical operations. There are two main segments to the company: Upstream and Downstream. The company's Upstream segment deals with the production, exploration, transport, and processing of crude oil and natural gases; as well as transportation and storage of natural gas. Refinery of crude oil is done by the Downstream segment. It also markets crude oil, refined products and lubricants. Transporting crude oil and refined products via pipelines, rail cars, motor vehicles, equipment and rail cars; as well as manufacturing and marketing commodity petrochemicals and plastics for industrial use and fuel additives. The company is involved in cash management, debt financing activities, insurance operations and real estate activities. In 2005, the company changed its name from ChevronTexaco Corporation to Chevron Corporation. Chevron Corporation was established in San Ramon in California in 1879.
Earnings Per Share
As for profitability, Chevron has a trailing twelve months EPS of $-4.12.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.24%.